Cladribine Ameliorates Imiquimod Induced Murine Psoriasiform Dermatitis
Jingwen Xue,1,2 Dan Shu,1,2 Yi Zhao1,2 1Department of Dermatology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, 102218, People’s Republic of China; 2Photomedicine Laboratory, Institute of Precision Medicine, Tsinghua University, Beijing, People’s Re...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-02-01
|
| Series: | Clinical, Cosmetic and Investigational Dermatology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/cladribine-ameliorates-imiquimod-induced-murine-psoriasiform-dermatiti-peer-reviewed-fulltext-article-CCID |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Jingwen Xue,1,2 Dan Shu,1,2 Yi Zhao1,2 1Department of Dermatology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, 102218, People’s Republic of China; 2Photomedicine Laboratory, Institute of Precision Medicine, Tsinghua University, Beijing, People’s Republic of ChinaCorrespondence: Yi Zhao, Department of Dermatology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, No. 168 Litang Road, Changping District, Beijing, 102218, People’s Republic of China, Email zhaoyimd@tsinghua.edu.cnBackground: Significant progress has been made in understanding the mechanisms of psoriasis, particularly the role of the interleukin (IL)-23/T-helper (Th) 17 axis, leading to novel, targeted therapies. However, many patients develop resistance to treatment over time. Thus, exploring new therapeutic strategies for severe refractory psoriasis remains crucial.Objective: To investigate the effect of cladribine on imiquimod induced psoriasiform dermatitis in mice.Methods: We established an imiquimod (IMQ)-induced psoriasiform dermatitis mouse model to investigate cladribine’s effects on skin immune cells. Mice were allocated to five groups: Control, IMQ, High-dose cladribine (30mg/kg), Low-dose cladribine (20mg/kg), and Methotrexate. We assessed cumulative scores, skin pathology, immunohistochemistry, flow cytometry, and serum cytokines. We also studied cladribine’s long-term efficacy by reapplying IMQ for a second round (7 days) after five half-lives of cladribine.Results: Cladribine significantly ameliorated symptoms and pathological features of IMQ-induced psoriasis in both high and low-dose groups, with efficacy comparable to methotrexate. Cladribine dose-dependently reduced Th17 and Th1 cell frequencies in psoriatic skin, along with associated cytokines. High-dose cladribine demonstrated sustained inhibition of IMQ-induced psoriasis.Conclusion: These findings indicate that cladribine can ameliorate imiquimod-induced psoriasiform dermatitis in mice, exhibiting a dose-dependent and sustained therapeutic effect.Keywords: cladribine, imiquimod-induced murine model, psoriasis |
|---|---|
| ISSN: | 1178-7015 |